Development of Tinnitus and Hyperacusis in a Mouse Model of Tobramycin Cochleotoxicity
Open Access
- 1 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 14
Abstract
Aminoglycosides (AG) antibiotics are a common treatment for recurrent infections in cystic fibrosis (CF) patients. AGs are highly ototoxic, resulting in a range of auditory dysfunctions. It was recently shown that the acoustic startle reflex (ASR) can assess behavioral evidence of hyperacusis and tinnitus in an amikacin cochleotoxicity mouse model. The goal of this study was to establish if tobramycin treatment led to similar changes in ASR behavior and to establish whether ebselen can prevent the development of these maladaptive neuroplastic symptoms. CBA/Ca mice were divided into three groups: Group 1 served as a control and did not receive tobramycin or ebselen, Group 2 received tobramycin (200 mg/kg/s.c.) and the vehicle (DMSO/saline/i.p.) daily for 14 continuous days, and Group 3 received the same dose/schedule of tobramycin as Group 2 and ebselen at (20 mg/kg/i.p.). Auditory brainstem response (ABR) and ASR hearing assessments were collected at baseline and 2, 6, 10, 14, and 18 weeks from the start of treatment. ASR tests included input/output (I/O) functions which assess general hearing and hyperacusis, and Gap-induced prepulse inhibition of the acoustic startle (GPIAS) to assess tinnitus. At 18 weeks, histologic analysis showed predominantly normal appearing hair cells and spiral ganglion neuron (SGN) synapses. Following 14 days of tobramycin injections, 16 kHz thresholds increased from baseline and fluctuated over the 18-week recovery period. I/O functions revealed exaggerated startle response magnitudes in 50% of mice over the same period. Gap detection deficits, representing behavioral evidence of tinnitus, were observed in a smaller subset (36%) of animals. Interestingly, increases in ABR wave III/wave I amplitude ratios were observed. These tobramycin data corroborate previous findings that AGs can result in hearing dysfunctions. We show that a 14-day course of tobramycin treatment can cause similar levels of hearing loss and tinnitus, when compared to a 14-day course of amikacin, but less hyperacusis. Evidence suggests that tinnitus and hyperacusis might be common side effects of AG antibiotics.Keywords
This publication has 95 references indexed in Scilit:
- Diminished Cortical Inhibition in an Aging Mouse Model of Chronic TinnitusThe Journal of Neuroscience, 2012
- Mechanisms of Aminoglycoside Ototoxicity and Targets of Hair Cell ProtectionInternational Journal of Otolaryngology, 2011
- Neurotoxic effects associated with antibiotic use: management considerationsBritish Journal of Clinical Pharmacology, 2011
- Development of Tinnitus in CBA/CaJ Mice Following Sound ExposureJournal of the Association for Research in Otolaryngology, 2011
- Mice with behavioral evidence of tinnitus exhibit dorsal cochlear nucleus hyperactivity because of decreased GABAergic inhibitionProceedings of the National Academy of Sciences, 2011
- Reversing pathological neural activity using targeted plasticityNature, 2011
- Ringing Ears: The Neuroscience of Tinnitus: Figure 1.The Journal of Neuroscience, 2010
- Supporting Cells Eliminate Dying Sensory Hair Cells to Maintain Epithelial Integrity in the Avian Inner EarJournal of Neuroscience, 2010
- Expression of Fractalkine Receptor CX3CR1 on Cochlear Macrophages Influences Survival of Hair Cells Following Ototoxic InjuryJournal of the Association for Research in Otolaryngology, 2009
- Tinnitus and inferior colliculus activity in chinchillas related to three distinct patterns of cochlear traumaJournal of Neuroscience Research, 2008